Analysts expect Sierra Oncology Inc (NASDAQ:SRRA) to report ($0.22) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Sierra Oncology’s earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.23). Sierra Oncology posted earnings of ($0.21) per share during the same quarter last year, which suggests a negative year over year growth rate of 4.8%. The firm is expected to report its next quarterly earnings results on Thursday, November 14th.
On average, analysts expect that Sierra Oncology will report full-year earnings of ($0.80) per share for the current year, with EPS estimates ranging from ($0.83) to ($0.76). For the next financial year, analysts anticipate that the firm will report earnings of ($0.84) per share, with EPS estimates ranging from ($0.91) to ($0.75). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Sierra Oncology.
Sierra Oncology (NASDAQ:SRRA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20).
Several research analysts have commented on SRRA shares. Zacks Investment Research cut shares of Sierra Oncology from a “buy” rating to a “hold” rating in a report on Friday. ValuEngine upgraded shares of Sierra Oncology from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC raised its position in Sierra Oncology by 22.0% in the 2nd quarter. Renaissance Technologies LLC now owns 2,312,634 shares of the biotechnology company’s stock valued at $1,295,000 after purchasing an additional 417,300 shares during the last quarter. Acadian Asset Management LLC raised its position in Sierra Oncology by 84.8% in the 2nd quarter. Acadian Asset Management LLC now owns 899,221 shares of the biotechnology company’s stock valued at $504,000 after purchasing an additional 412,728 shares during the last quarter. JPMorgan Chase & Co. raised its position in Sierra Oncology by 981.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 43,703 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 39,661 shares during the last quarter. Virtu Financial LLC purchased a new stake in Sierra Oncology in the 1st quarter valued at $32,000. Finally, Brookstone Capital Management purchased a new stake in Sierra Oncology in the 1st quarter valued at $28,000. Institutional investors own 62.61% of the company’s stock.
NASDAQ SRRA remained flat at $$0.43 on Monday. 184,600 shares of the company’s stock traded hands, compared to its average volume of 406,235. The company has a current ratio of 9.24, a quick ratio of 13.07 and a debt-to-equity ratio of 0.06. Sierra Oncology has a 12 month low of $0.40 and a 12 month high of $2.07. The firm has a market cap of $32.85 million, a P/E ratio of -0.57 and a beta of 1.24. The firm has a fifty day simple moving average of $0.53 and a 200-day simple moving average of $1.20.
Sierra Oncology Company Profile
Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.
See Also: Do investors pay a separate front-end load every time they buy additional shares?
Get a free copy of the Zacks research report on Sierra Oncology (SRRA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.